Furthermore, inhibitors of IRAK1 pacritinib upregulated PD-L1 expression in several cancer cell lines, indicating that the pharmacological inhibition of IRAK1 could be synergistic with immunotherapy in the future. This evidence concerns the gene CD274 and cancer.